Background {#Sec1}
==========

Medulloblastoma (MB), the most common pediatric brain tumor, constitutes nearly 20% of newly diagnosed brain tumors in children \[[@CR1], [@CR2]\]. Treatment of MB involves radiation therapy, chemotherapy and surgical resection. These strategies have improved the survival by 70--80% but also lead to serious morbidities \[[@CR3], [@CR4]\]. MB are classified into four major molecular subgroups as WNT, Sonic hedgehog (SHH), Group 3 and Group 4. The WNT subgroup is least common among all 4 subgroups and present in only 10% of cases. Genetic changes in genes: *CTNNB1*, *DDX3X*, *SMARCA4* and *DKK1* are frequently observed in the WNT subgroup. WNT has the best prognosis among all types of MB. SHH is second most common subgroup with abnormalities in SHH signaling pathway and accounts for \~ 30% of total MB cases. Genetic anomalies in genes: *MYCN*, *GLI1*, *PTCH1*, *SUFU*, *MLL2*, *SMO*, *TP53*, *BCOR1*, *GAB1*, *GABRG1* and *LDB1* are frequently seen in the SHH subgroup. The SHH subgroup has an intermediate prognosis among MB subgroups. Group 3 is the third most common subgroup with 25% of the total MB cases. Group 3 is mainly MYC-driven and genetic aberrations are seen in genes: *MYC*, *PVT1*, *OTX2*, *MLL2*, *SMARCA4*, and *CHD7* in this subgroup. The prognosis of the Group 3 is very poor and 5 year overall survival is less than 50%. Group 4 is the most common subgroup of MB and accounts for 35% of total cases. The prognosis of the Group 4 is intermediate and genetic aberrations are commonly present in genes: *OTX2*, *DDX31*, *CHD7*, *NCAIP*, *MYCN*, *CDK6*, *GFI1*/*GFI1B*, *MLL2*, *KDM6A*, *MLL3*, and *ZMYM3* \[[@CR5]--[@CR9]\]. Molecular markers used for WNT identification are CTNNB1 (nuclear), FLIA, YAP1 and DKK1; for SHH are SFRP1, GLI1, FLIA, YAP1 and GAB1; for Group 3, NPR3; and for Group 4, KCNA1. Identification of new molecular markers for drug targeting, diagnosis and prognosis are important due to need for improved molecular profiling of MB \[[@CR10]\].

Long non-coding RNAs (LncRNAs) are RNAs of more than 200 bp in length and can be transcribed from an intergenic region, genic regions or super enhancer regions in the genome. LncRNAs can modulate chromatin structure, gene regulation via interactions with epigenetic modifiers and transcriptional co-factors, and also have post-translation effects via affecting the stability of mRNA or proteins \[[@CR11], [@CR12]\]. Deregulated lncRNA expression is associated with many cancers \[[@CR13]\]. LncRNA signatures have been used to classify different types of cancer as biomarkers for diagnosis, prognosis and therapy \[[@CR14]--[@CR18]\]. LncRNAs are secreted in serum, plasma, and CSF in a stable form protected from endogenous RNAase and can be used for non-invasive analysis from patient samples \[[@CR19], [@CR20]\]. The role of lncRNA in brain development is well studied \[[@CR21]--[@CR26]\]. However, there is not much known about role of lncRNAs in MB. LncRNA LOXL1-AS1 promotes the proliferation and metastasis of MB by activating the PI3K-AKT pathway \[[@CR27]\]. LncRNA CCAT1 promotes cell proliferation and metastasis in human MB by regulating the MAPK pathway \[[@CR28]\]. Silencing of ANRIL in MB cell lines significantly lowered cell viability and migration. ANRIL promoted the apoptosis of MB cell lines through miR-323-mediated regulation of BRI3, which activates p38 MAPK, ERK, and AKT as well as the WNT signaling pathway \[[@CR29]\]. LINC-NeD125 expression is upregulated in Group 4 MB and after interacting to miRNA-induced silencing complex(MISC), it directly binds to miR-19a-3p, miR-19b-3p and miR-106a-5p. Functionally, LINC-NeD125 acts by sequestering the three miRNAs, which leads to the de-repression of major driver genes (*CDK6*, *MYCN*, *SNCAIP*, and *KDM6A*) of Group 4 MB \[[@CR30]\]. LncRNA CRNDE expression is elevated in MB and knockdown of CRNDE significantly reduced cell proliferation and inhibited colony formation in MB cell lines, Daoy and D341 \[[@CR31]\].

In the current study, we have identified the lncRNAs expression profile of pediatric MB subgroups and associated molecular pathways. We have also identified the unique lncRNAs associated with each subgroup.

Methods {#Sec2}
=======

We searched the Gene Expression Omnibus (GEO) database for MB related microarray datasets and found two relevant studies, GSE37418 \[for pediatric MB subgroups expression data\] and GSM1094863, GSM1094864, GSM1094865, GSM1094866, GSM1094867 \[for pediatric primary cerebellum expression data from GSE44971\] for our analyses. We further used large GSE124814 datasets for the validation of lncRNAs expression profiles of MB subgroups obtained from our original analyses. We selected the age \< 18 years as an inclusion criteria for selecting pediatric MB samples. We selected the datasets which used the Affymetrix U133 Plus2 array for probe level RNA expression studies. For data analyses, we first did background correction, normalization (RMA), quality control checks, intensity and batch effect corrections of each dataset. Following that, we did probe level differential analyses of datasets using the limma package (ANOVA with eBayes) with criteria of *p* \< 0.001 and fold change greater than two folds. We then annotated the probe sets with the Affymetrix U133 Plus2 library and filtered out lncRNA genes. The lncRNA gene database used is verified and approved by HGNC. Functional analysis of differentially expressed lncRNAs was done by Ingenuity pathway analysis (IPA) software from BioRad, Inc. We used default parameters and checked all the node types, all species (except uncharted), and all tissue types for core analysis in IPA.

Results {#Sec3}
=======

Differentially expressed lncRNAs in the WNT subgroup and their functional roles {#Sec4}
-------------------------------------------------------------------------------

Comparative analyses of WNT MB (*N* = 8) and normal cerebellum tissue (*N* = 5) datasets with *p* \< 0.05 and fold changes \> 2 provided 199 differentially expressed lncRNAs with approved status. Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} show the fold change in the top 10 upregulated and downregulated lncRNAs. Heatmap of top 10 upregulated and downregulated lncRNAs is shown in Fig. [1](#Fig1){ref-type="fig"}a. The complete list of lncRNAs can be seen in Additional file [1](#MOESM1){ref-type="media"}. We found 73% overlap with lncRNAs in validation datasets \[WNT *N* = 31, Control = 5\] (Additional file [2](#MOESM2){ref-type="media"}). We found all the top 10 upregulated and downregulated lncRNAs present in validation datasets. We mostly see non-overlap in lncRNAs at lower expression values. Table 1Top 10 up-regulated lncRNAs in WNT subgroup of MBGene SymbolFold ChangeP-valFDR P-valEMX2OS38.189.01E-144.92E-10OTX2-AS137.841.14E-093.93E-07PGM5-AS130.269.54E-091.63E-06DSCR824.560.00010.0013LOXL1-AS121.061.03E-081.73E-06HAND2-AS118.519.37E-073.59E-05TMEM51-AS116.93.88E-098.82E-07RMST13.921.14E-078.49E-06LINC0130511.110.00010.001PART110.941.89E-050.0003Table 2Top 10 down-regulated lncRNAs in WNT subgroup of MBGene SymbolFold Change*P*-valFDR *P*-valLINC00461−62.391.16E-064.17E-05MEG3−58.99.41E-073.60E-05LINC00844−24.940.00030.0024LINC00643−13.36.95E-060.0001SOX2-OT−12.130.00030.0024PEG3-AS1−10.023.49E-071.84E-05TUNAR−7.722.04E-125.87E-09MALAT1−7.391.65E-071.10E-05LINC01105−7.393.77E-050.0005LINC01351−6.482.24E-050.0003Fig. 1**a**: Heatmap of top 10 upregulated and downregulated lncRNAs in WNT subgroup. Expression value of different lncRNAs was clustered using correlation distance method. **b**: Differentially expressed lncRNAs in a non-canonical biological network in WNT subgroup. The important nodes in this biological network are CCND1, AKT, SOX2, POU5F1, DNMT3B, and CTNNB1. **c**: Differentially expressed lncRNAs in another non-canonical biological network in WNT subgroup. The important nodes in this biological network are TP53, MYC, EZH2, and MDM2. Green indicates downregulated and red indicates upregulated lncRNAs

We did functional analysis of differentially expressed (DE) lncRNAs of the WNT subgroup using IPA. We identified different functional parameters involved in this subgroup. MAX (a MYC interacting partner), miR-150, miR-133a, FOLR1, E2F NCAM1, GAS2L3 and ATF5 are the most significantly associated upstream regulators, while cancer, neurogenesis, metastasis and cellular development are the most important biological functions affected in this subgroup (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Heatmap of 5 upstream regulators is shown in supplementary Fig. [1](#Fig1){ref-type="fig"} (Additional file [3](#MOESM3){ref-type="media"}). The two most important non-canonical networks enriched with DE lncRNAs are shown in Fig. [1](#Fig1){ref-type="fig"}b and c. In networks 1; CCND1, AKT, SOX2, POU5F1, DNMT3B, and CTNNB1, in network 2; TP53, MYC, EZH2, and MDM2 are the central regulators linked with DE lncRNAs. Table 3Top 10 upstream regulators involved in DE lncRNAs in WNT subgroupUpstream RegulatorMolecule Type*P*-val of overlapTarget molecules in datasetMAXtranscription regulator5.53E-03DLEU1,DLEU2miR-150-5p (and other miRNAs w/seed CUCCCAA)mature microRNA5.54E-03MIATmiR-133a-3p (and other miRNAs w/seed UUGGUCC)mature microRNA7.38E-03MALAT1mir-133microRNA9.22E-03MALAT1FOLR1transporter1.31E-02GAS5,PVT1E2fgroup1.37E-02DLEU1,DLEU2ATF5transcription regulator1.47E-02GAS5NCAM1other1.84E-02MALAT1mir-150microRNA2.56E-02MIATGAS2L3other2.92E-02PVT1Table 4Top 10 disease and function identified by IPA from DE lncRNAs in WNT subgroupCategoriesDiseases or Functions Annotation*P*-valActivation z-scoreCellular Development, Cellular Growth and Proliferation, Nervous System Development and FunctionNeurogenesis of nervous tissue cell lines3.38E-06Cellular MovementCell movement of tumor cell lines1.12E-051.324Cellular MovementMigration of tumor cell lines1.14E-051.498Cellular MovementInvasion of tumor cell lines1.55E-041.083Cell CycleArrest in G0 phase of tumor cell lines3.83E-04Cancer, Organismal Injury and AbnormalitiesMetastasis of tumor cell lines4.26E-04−0.277Cell Death and SurvivalCell death of eye cell lines5.07E-04Cellular MovementMigration of cells6.27E-040.573Cellular MovementCell movement6.75E-040.453Cellular MovementMigration of hepatoma cell lines1.34E-03

Differentially expressed lncRNAs in the SHH subgroup and their functional roles {#Sec5}
-------------------------------------------------------------------------------

Comparative analyses of the SHH subgroup (*N* = 10) and normal cerebellum tissue (*N* = 5) datasets with *p* \< 0.05 and fold change \> 2 provided 145 differentially expressed lncRNAs with approved status. Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} show the fold change in the top 10 upregulated and downregulated lncRNAs. Heatmap of top 10 upregulated and downregulated lncRNAs is shown in Fig. [2](#Fig2){ref-type="fig"}a. The complete list of lncRNAs can be seen in Additional file [1](#MOESM1){ref-type="media"}. We found 50% overlap with lncRNAs in validation datasets \[SHH *N* = 65, Control = 5\] (Additional file [2](#MOESM2){ref-type="media"}). We found all the top 10, upregulated and downregulated lncRNAs, present in validation datasets except DLEU2 and PRR34-AS1. Table 5Top 10 up-regulated lncRNAs in SHH subgroup of MBGene SymbolFold Change*P*-valFDR *P*-valNEAT123.480.00030.0022DLEU213.245.79E-112.41E-08PRR34-AS18.071.58E-078.49E-06LINC013558.052.93E-095.15E-07MIRLET7BHG7.491.79E-079.34E-06CKMT2-AS16.231.86E-093.59E-07SLC16A1-AS15.658.13E-085.36E-06TPT1-AS15.284.44E-083.50E-06LINC010004.961.10E-081.32E-06ANP32A-IT14.949.36E-073.07E-05Table 6Top 10 down-regulated lncRNAs in SHH subgroup of MBGene SymbolFold Change*P*-valFDR *P*-valLINC00844−33.361.08E-081.32E-06MIR124-2HG−28.130.00050.0032SOX2-OT−13.832.39E-071.15E-05PEG3-AS1−12.945.12E-083.88E-06LINC00643−11.763.97E-068.83E-05HCG11−11.260.00120.0065RMST−9.430.00360.0155CCEPR−8.931.49E-064.27E-05MEG3−8.530.00020.0018MALAT1−8.252.82E-066.86E-05Fig. 2**a**: Heatmap of top 10 upregulated and downregulated lncRNAs in SHH subgroup. Expression value of different lncRNAs was clustered using correlation distance method. **b**: Differentially expressed lncRNAs in a non-canonical biological network in SHH subgroup. The important nodes in this biological network are CCND1, TP53, MYC, MALAT1, CTNNB1, and SP1. **c**: Differentially expressed lncRNAs in another non-canonical biological network in SHH subgroup. The important nodes in this biological network are Histone H3, MDM2, CCNA2, SOX2, POU2F1, SP1, and ESR1. Green indicates downregulated and red indicates upregulated lncRNAs

Functional analysis of DE lncRNAs of SHH MB subgroup using IPA predicts, MAX (a MYC interacting partner), miR-133a, FOLR1, E2F, ATF5, AM1, E2F3, GAS2L3 and ACSL5 as most significantly associated upstream regulators, while cancer, neurogenesis, cell proliferation, metastasis and cellular development are the most important biological functions affected in this subgroup (Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}). Heatmap of 5 upstream regulators is shown in supplementary Fig. 1 (Additional file [3](#MOESM3){ref-type="media"}). The two most important non-canonical networks enriched with DE lncRNAs are shown in Fig. [2](#Fig2){ref-type="fig"}b and c. In network 1; CCND1, TP53, MYC, MALAT1, CTNNB1, and SP1, in network 2; Histone H3, MDM2, CCNA2, SOX2, POU2F1, SP1, and ESR1 are the central regulators linked with DE lncRNAs. Table 7Top upstream regulators involved in DE lncRNAs in SHH subgroupUpstream RegulatorMolecule Type*P*-val of overlapTarget molecules in datasetMAXtranscription regulator2.74E-03DLEU1,DLEU2miR-133a-3p (and other miRNAs w/seed UUGGUCC)mature microRNA5.17E-03MALAT1mir-133microRNA6.46E-03MALAT1FOLR1transporter6.58E-03GAS5,PVT1E2fgroup6.85E-03DLEU1,DLEU2ATF5transcription regulator1.03E-02GAS5NCAM1other1.29E-02MALAT1E2F3transcription regulator1.49E-02MALAT1,NEAT1GAS2L3other2.05E-02PVT1ACSL5enzyme2.18E-02ST7-AS1Table 8Top 10 disease and function identified by IPA from DE lncRNAs in SHH subgroupCategoriesDiseases or Functions Annotation*P*-valActivation z-scoreCellular Development, Cellular Growth and Proliferation, Nervous System Development and FunctionNeurogenesis of nervous tissue cell lines1.79E-06Cellular Development, Cellular Growth and ProliferationProliferation of kidney cancer cell lines3.01E-06−0.095Cellular Development, Cellular Growth and ProliferationCell proliferation of tumor cell lines3.90E-040.933Cellular MovementMigration of carcinoma cell lines5.25E-040.762Cellular MovementMigration of kidney cancer cell lines6.63E-04Cellular MovementCell movement of tumor cell lines6.65E-040.751Cellular MovementMigration of tumor cell lines1.14E-031.033Cellular Development, Cellular Growth and ProliferationCell proliferation of carcinoma cell lines1.30E-030.277Cellular Development, Connective Tissue Development and Function, Tissue DevelopmentOsteogenic differentiation of nucleus pulposus cells1.36E-03Cancer, Gastrointestinal Disease, Organismal Injury and AbnormalitiesStage I colorectal adenocarcinoma1.36E-03

Differentially expressed lncRNAs in the Group 3 subgroup and their functional roles {#Sec6}
-----------------------------------------------------------------------------------

Comparative analyses of the Group 3 MB (*N* = 16) and normal cerebellum tissue (*N* = 5) datasets with *p* \< 0.05 and fold change \> 2 provided 149 differentially expressed lncRNAs with approved status. Tables [9](#Tab9){ref-type="table"} and [10](#Tab10){ref-type="table"} show the fold change in the top 10 upregulated and downregulated lncRNAs. Heatmap of top 10 upregulated and downregulated lncRNAs is shown in Fig. [3](#Fig3){ref-type="fig"}a. The complete list of lncRNAs can be seen in Additional file [1](#MOESM1){ref-type="media"}. We found 86% overlap with lncRNAs in validation datasets \[Group 3 *N* = 46, Control N = 5\] (Additional file [2](#MOESM2){ref-type="media"}). We found all the top 10 upregulated and downregulated lncRNAs in the validation dataset, except NEAT1. Table 9Top 10 up-regulated lncRNAs in Group 3 of MBGene SymbolFold Change*P*-valFDR *P*-valOTX2-AS180.961.03E-141.38E-11BLACAT124.596.32E-083.32E-06LINC0034819.060.00130.0077LINC013559.911.54E-081.09E-06DLEU28.972.31E-092.49E-07PGM5-AS17.734.32E-050.0005NEAT17.270.00820.0315DSCR86.730.01040.0378PRR34-AS16.631.37E-063.58E-05MIRLET7BHG6.320.00040.003Table 10Top 10 down-regulated lncRNAs in Group 3 of MBGene SymbolFold Change*P*-valFDR *P*-valXIST−315.10.00660.0267MEG3−58.010.00010.0011SOX2-OT−50.31.15E-141.44E-11LINC00844−37.66.71E-083.47E-06MIR100HG−16.611.16E-063.15E-05HCG11−12.991.93E-050.0003MIAT−10.360.00020.0016LINC00461−9.380.0020.0105LINC00643−9.340.00050.0036TRHDE-AS1−7.597.27E-096.14E-07Fig. 3**a**: Heatmap of top 10 upregulated and downregulated lncRNAs in Group 3 MB. Expression value of different lncRNAs was clustered using correlation distance method. **b**: Differentially expressed lncRNAs in a non-canonical biological network in Group 3 MB. The important nodes in this biological network are CCND1, EP300, CREBBP, ESR1, CTNNB1, and PRKCD. **c**: Differentially expressed lncRNAs in another non-canonical biological network in Group 3 MB. The important nodes in this biological network are Histone H3, TP53, MYC, XIST, and EZH2. Green indicates downregulated and red indicates upregulated lncRNAs

Functional analysis of DE lncRNAs of Group 3 MB using IPA predicted C17orf98, ZNF426, RNF165, FBXO8, CTCF, LAYN, PYGO1, Firre, TSIX and miR-150-5pa as most significantly associated upstream regulators, while activation/inactivation of X-chromosome, cell movement, and metastasis are the most important biological functions affected in this subgroup (Tables [11](#Tab11){ref-type="table"} and [12](#Tab12){ref-type="table"}). Heatmap of 5 upstream regulators is shown in supplementary Fig. 2 (Additional file [3](#MOESM3){ref-type="media"}). The two most important non-canonical networks enriched with DE lncRNAs are shown in Fig. [3](#Fig3){ref-type="fig"}b and c. In network 1; CCND1, EP300, CREBBP, ESR1, CTNNB1, and PRKCD, in network 2; Histone H3, TP53, MYC, XIST, and EZH2 are the central regulators linked with DE lncRNAs. Table 11Top 10 upstream regulators involved in DE lncRNAs in Group 3 MBUpstream RegulatorMolecule Type*P*-val of overlapTarget molecules in datasetC17orf98other1.11E-03XISTZNF426transcription regulator1.11E-03XISTRNF165enzyme1.11E-03XISTFBXO8other1.11E-03XISTCTCFtranscription regulator2.08E-03TSIX,XISTLAYNother2.22E-03XISTPYGO1other2.22E-03XISTFirreother3.33E-03XISTTSIXother3.33E-03XISTmiR-150-5p (and other miRNAs w/seed CUCCCAA)mature microRNA3.33E-03MIATTable 12Top 10 disease and function identified by IPA from DE lncRNAs in Group 3 MBCategoriesDiseases or Functions Annotation*P*-valActivation z-scoreGene ExpressionInactivation of mouse X chromosome5.74E-06Gene ExpressionActivation of mouse X chromosome5.74E-06Cellular MovementCell movement of tumor cell lines2.36E-050.783Cellular MovementMigration of tumor cell lines3.60E-050.955Cell CycleArrest in G0 phase of tumor cell lines1.65E-04Cellular MovementInvasion of tumor cell lines6.99E-040.495Cellular MovementCell movement1.30E-030.804Gene ExpressionImprinting1.31E-03Cancer, Organismal Injury and AbnormalitiesMetastasis of tumor cell lines1.32E-030.152Hereditary Disorder, Organismal Injury and AbnormalitiesFamilial skewed X inactivation1.41E-03

Differentially expressed lncRNAs in the Group 4 MB and their functional roles {#Sec7}
-----------------------------------------------------------------------------

Comparative analyses of Group 4 MB (*N* = 39) and normal cerebellar tissue (*N* = 5) datasets with *p* \< 0.05 and fold change \> 2 provided 150 differentially expressed lncRNAs with approved status. Tables [13](#Tab13){ref-type="table"} and [14](#Tab14){ref-type="table"} show the fold change in the top 10 upregulated and downregulated lncRNAs. Heatmap of top 10 upregulated and downregulated lncRNAs is shown in Fig. [4](#Fig4){ref-type="fig"}a. The complete list of lncRNAs can be seen in Supplementary file 1. We found 82% overlap with lncRNAs in validation datasets \[Group 4 *N* = 95, Control = 5\] (Additional file [2](#MOESM2){ref-type="media"}). We found all the top 10 upregulated and downregulated lncRNAs in validation datasets. Table 13Top 10 up-regulated lncRNAs in Group 4 of MBGene SymbolFold Change*P*-valFDR *P*-valLINC01419139.780.00470.0175OTX2-AS160.129.95E-162.03E-13BLACAT127.671.13E-184.59E-16DLEU211.582.25E-154.16E-13LINC013557.092.23E-073.85E-06MIRLET7BHG7.012.03E-062.55E-05PRR34-AS16.828.84E-126.11E-10LINC010006.294.10E-123.13E-10CKMT2-AS16.195.04E-112.82E-09MIR99AHG5.279.82E-071.38E-05Table 14Top 10 down-regulated lncRNAs in Group 4 of MBGene SymbolFold Change*P*-valFDR *P*-valXIST− 343.060.02870.0745SOX2-OT−31.61.90E-132.06E-11MALAT1−13.085.80E-102.34E-08LINC00643−11.644.39E-134.32E-11LINC00844−9.891.26E-050.0001LRRC75A-AS1−9.531.52E-083.87E-07MIAT−7.872.15E-109.90E-09PRKAG2-AS1−7.84.29E-076.75E-06NR2F1-AS1−5.988.89E-114.63E-09PEG3-AS1−5.741.92E-084.73E-07Fig. 4**a**: Heatmap of top 10 upregulated and downregulated lncRNAs in Group 4 MB. Expression value of different lncRNAs was clustered using correlation distance method. **b**: Differentially expressed lncRNAs in a non-canonical biological network in Group 4 MB. The important nodes in this biological network are AR, MYC, XIST, SP1, CCND1, and EZH2. **c**: Differentially expressed lncRNAs in another non-canonical biological network in Group 4 MB. The important nodes in this biological network are Histone H3, SP1, ESR1, MYC, SOX2, POU5F1, CDH1, and CEBPB. Green indicates downregulated and red indicates upregulated lncRNAs

Functional analysis of DE lncRNAs of Group 4 MB using IPA predicted C17orf98, ZNF426, RNF165, FBXO8, CTCF, LAYN, PYGO1, Firre, TSIX and miR-150-5pa as most significantly associated upstream regulators, while activation/inactivation of X-chromosomes, cell movement, methylation of DNA and metastasis are the most important biological functions affected in this subgroup (Tables [15](#Tab15){ref-type="table"} and [16](#Tab16){ref-type="table"}). Heatmap of 5 upstream regulators is shown in supplementary Fig. 2 (Additional file [3](#MOESM3){ref-type="media"}). The two important non-canonical networks enriched with DE lncRNAs are shown in Fig. [4](#Fig4){ref-type="fig"}b and c. In network 1; AR, MYC, XIST, SP1, CCND1, and EZH2, in network 2; Histone H3, SP1, ESR1, MYC, SOX2, POU5F1, CDH1, and CEBPB are the central regulators linked with DE lncRNAs. Table 15Top 10 upstream regulators involved in DE lncRNAs in Group 4 MBUpstream RegulatorMolecule Type*P*-val of overlapTarget molecules in datasetC17orf98other1.34E-03XISTZNF426transcription regulator1.34E-03XISTRNF165enzyme1.34E-03XISTFBXO8other1.34E-03XISTLAYNother2.68E-03XISTPYGO1other2.68E-03XISTCTCFtranscription regulator3.03E-03TSIX,XISTFirreother4.02E-03XISTTSIXother4.02E-03XISTmiR-150-5p (and other miRNAs w/seed CUCCCAA)mature microRNA4.02E-03MIATTable 16Top 10 disease and function identified by IPA from DE lncRNAs in Group 4 MBCategoriesDiseases or Functions Annotation*P*-valActivation z-scoreCellular MovementCell movement of tumor cell lines4.56E-06−0.938Gene ExpressionInactivation of mouse X chromosome6.13E-06Gene ExpressionActivation of mouse X chromosome6.13E-06Cellular MovementMigration of tumor cell lines6.36E-06−0.877Gene ExpressionImprinting2.27E-05Cell Death and SurvivalApoptosis of kidney cancer cell lines3.30E-05Cancer, Organismal Injury and AbnormalitiesMetastasis of tumor cell lines1.28E-040.555Cellular MovementInvasion of tumor cell lines1.36E-040.031Cellular Development, Cellular Growth and ProliferationProliferation of kidney cancer cell lines1.68E-04DNA Replication, Recombination, and Repair, Gene ExpressionMethylation of DNA1.82E-04Cell Death and SurvivalCell death of eye cell lines3.08E-04

Prognostic significance of lncRNAs in different subgroups of MB {#Sec8}
---------------------------------------------------------------

We used a publicly available dataset GSE85217 (Cavalli dataset) to understand the prognostic significance of DE lncRNAs of different MB subgroups. As shown in Fig. [5](#Fig5){ref-type="fig"}, high expression of HAND2-AS1 is associated with poor prognosis in WNT MB. Similarly, low expression of MEG3 in SHH, high expression of DLEU2 and DSCR8 in Group 3 and high expression of DLEU2 and low expression of XIST in Group 4 are associated with poor prognosis in MB (*p* \< 0.05). Fig. 5Kaplan Meier survival curves of different lncRNAs expressed in different subgroups of MB (Cavalli dataset) obtained using scan cut-off method on hgserver ([https://hgserver1.amc.nl](https://hgserver1.amc.nl/)). **a**: High expression of HAND2-AS1 is associated with poor prognosis in WNT MB. **b**: Low expression of MEG3 is associated with poor prognosis in SHH MB. **c**: High expression of DLEU2 and DSCR8 are associated with poor prognosis in Group 3 MB. **d**: High expression of DLEU2 and low expression of XIST in Group 4 MB are associated with poor prognosis (*p* \< 0.05)

Discussion {#Sec9}
==========

LncRNAs are known regulators of gene expression. Disruptions in gene regulatory pathways in cancers dictate the aberrant LncRNAs expression \[[@CR11]--[@CR13]\]. Notably, almost 40% of lncRNAs are aberrantly expressed in the brain-related disorders including brain tumors. However, lncRNA expression profile in MB is largely unexplored. In this study, we have identified the lncRNA expression profile of pediatric MB subgroups and associated molecular pathways. The identified key lncRNAs require further functional validation in vitro and in vivo to explore their potential role in MB subgroup-specific manner. Here, we discuss the known cancer-relevant function of the key lncRNAs identified in MB subgroups.

EMX2OS is the most differentially expressed lncRNA in the WNT subgroup. This lncRNA is known to regulate *EMX* gene expression in the brain development \[[@CR32], [@CR33]\]. OTX2-AS1 (antisense strand of the *OTX2* gene) is predominantly involved in eye development \[[@CR34]\]. High PGM5-AS1 (antisense strand of the *PGM5* gene) expression is associated with development and poor prognosis of colorectal cancer (CRC) \[[@CR35]\]. Increased expression of DSCR8 is associated to malignant pathology and poor survival in hepatocellular carcinoma (HCC) patients \[[@CR36]\]. LOXL1-AS1 (antisense strand of the *LOXL1* gene) is involved in the progression and metastasis of MB by regulating the PI3K-AKT signaling \[[@CR27]\]. In addition, it is also known to play roles in the proliferation and survival of prostate cancer (PC) cells via miR-541-3p and cell cycle gene *CCND1* \[[@CR37]\] as well as aggressive nature of glioblastoma by activating NF-kB pathway \[[@CR38]\]. HAND2-AS1 (antisense strand of the *HAND2* gene) is overexpressed in esophageal squamous cell carcinoma (ESCC) \[[@CR39]\] while it is downregulated in non-small cell lung cancer (NSCLC) cells \[[@CR40]\]. TMEM51-AS1 (antisense strand of the *TMEM51* gene) is associated with renal cell carcinoma (RCC) \[[@CR41]\]. RMST acts as a tumor suppressor in triple-negative breast cancer (TNBC) by inducing apoptosis and inhibiting proliferation/invasion and migration \[[@CR42]\]. PART1 promotes gefitinib-resistance in ESCC by regulating the miR-129/Bcl-2 pathway \[[@CR43]\] and also associated with PC tumorigenesis \[[@CR44]\]. LINC00461 is involved in glioma tumorigenesis via MAPK/ERK and PI3K/AKT signaling pathways \[[@CR45]\]. Downregulation of MEG3 is involved in the proliferation and apoptosis of PC cells by regulating miR-9-5p and its target gene *QKI-5* \[[@CR46]\]. Downregulation of LINC00844 is associated with poor clinical outcomes and suppressed tumor progression/metastasis in PC \[[@CR47]\]. SOX2-OT is overexpressed and promotes tumorigenesis by upregulating *SOX2* gene and activating PI3K/AKT signaling pathway in cholangiocarcinoma (CCA) \[[@CR48]\]. SOX2-OT is also a prognostic biomarker for osteosarcoma (OS) and involved in cell survival and cancer stem cells \[[@CR49]\]. TUNAR plays a tumor suppressive role in glioma cells by upregulating miR-200a and inhibiting Rac1 \[[@CR50]\]. MALAT1 promotes the chemo-resistance of cervical cancer via BRWD1-PI3K/AKT pathway \[[@CR51]\]. MALAT1 is a well-studied lncRNA in several solid and hematological cancers \[[@CR52]\].

NEAT1 is overexpressed in most cancer types, except leukemia and myeloma, where it is down-regulated \[[@CR53]--[@CR55]\]. DLEU2 exhibits role in the proliferation and survival of laryngeal cancer cells via miR-16-1 \[[@CR56]\]. DLEU2 is also significantly overexpressed in gastric cancer and contributes to cell proliferation \[[@CR57]\]. TPT1-AS1 (antisense strand of the *TPT1* gene) expression is upregulated in cervical cancer and has influence on proliferation and migration \[[@CR58]\]. HCG11 is significantly overexpressed in hepatocellular carcinoma (HCC) and genetic-silencing of HCG11 in HCC cells leads to decreased proliferation \[[@CR59]\]. HCG11 expression is downregulated in PC and associated with poor prognosis of patients \[[@CR60]\]. CCEPR contributes significantly in promoting cell proliferation and inhibiting apoptosis in bladder cancer \[[@CR61]\].

BLACAT1 is overexpressed in chemo-resistant NSCLC and induces autophagy by regulating miR-17 and ATG7 pathway \[[@CR62]\]. It also triggers proliferation/survival by regulating WNT signaling in cervical cancer \[[@CR63]\].

XIST is elevated in bladder cancer and inhibits p53 function via binding to TET1 \[[@CR64]\]. XIST also binds to miR-34a and elicits proliferation and tumor development in thyroid cancer \[[@CR65]\]. XIST is an important regulator of progression and oxaliplatin-resistance in malignant melanoma \[[@CR66]\]. MIR100HG is known to be involved in cetuximab-resistance in CRC via the β-catenin cellular pathway \[[@CR67]\]. In addition, elevated expression of MIR100HG is correlated with poor prognosis of osteosarcoma \[[@CR68]\]. MIAT is overexpressed in clear cell renal cell carcinoma (CCRCC) and associated with poor prognosis \[[@CR69]\]. MIAT associates with miR-133 and contributes a role in the progression pancreatic cancer development \[[@CR70]\]. MIAT also plays a key role in CRC tumorigenesis via miR-132/Derlin-1 axis \[[@CR71]\]. NR2F1-AS1 (antisense strand of the *NR2F1* gene) promotes chemotherapy-resistance in HCC by regulating miR-363-ABCC1 drug-transporter pathway \[[@CR72]\].

Conclusions {#Sec10}
===========

We propose that the majority of DE lncRNAs in MB might have oncogenic properties as seen in other cancers (Supplementary Table S1 in Additional file [3](#MOESM3){ref-type="media"}) \[[@CR73]--[@CR82]\]. We found approximately 25% of these DE lncRNAs in MB are tumor suppressive. Also, each MB subgroup has unique and common lncRNAs in their expression profile (Fig. [6](#Fig6){ref-type="fig"}). We performed a unique lncRNAs analysis in both original datasets and validation datasets (Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}). Unique lncRNAs can be validated for differential diagnosis and prognosis of MB subgroups. Common lncRNAs and associated molecules in pathways can be important therapeutic targets. We identified important lncRNAs DELU2, CASC15, LINC01355 and GAS5 are present in each subgroup and can be further explored for functional analyses in different MB subgroups. We also found SOX2, Protein kinase C delta (PRKCD), and EZH2 associated with functional networks of each subgroup and could be important drug targets. We also identified the prognostic significance of lncRNAs in different subgroups of MB. Fig. 6Venn diagram shows unique and overlapping lncRNAs profile in different MB subgroups. A complete list of unique lncRNAs in each subgroup can be viewed in supplementary file (highlighted in purple in Additional file [1](#MOESM1){ref-type="media"})
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MB

:   Medulloblastoma

LncRNAs

:   Long-non-coding RNAs

GEO

:   Gene Expression Omnibus

DE

:   Differentially expressed

mRNA

:   Messenger ribonucleic acid

DNA

:   Deoxyribonucleic acid

IPA

:   Ingenuity pathway analysis

ANOVA

:   Analysis of variance
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